Vitiligo
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Vitiligo ya zala ndizovuta kwambiri kuchiza kuposa madera ena. Kupatulapo kukhala wosawoneka bwino, vitiligo ndi wabwinobwino ndipo sipatsirana. Mu dermatology, chithandizo chothandiza kwambiri ndi phototherapy kapena laser treatment (excimer) 2-3 pa sabata kwa chaka chimodzi. Ngati simungathe kupita kuchipatala nthawi zambiri chifukwa chandalama kapena chifukwa chotanganidwa, mutha kuyesa makina a phototherapy omwe amavomerezedwa kuti agwiritsidwe ntchito kunyumba.
Eyelid vitiligo
Vitiligo pa dzanja
References
Vitiligo ndi matenda ofala pakhungu omwe amayambitsa zigamba pakhungu loyera chifukwa cha kutayika kwa ma melanocyte. Kafukufuku waposachedwa akuwonetsa kuti ndi matenda a autoimmune. Ngakhale kuti nthawi zambiri imawoneka ngati nkhani yodzikongoletsera, imatha kukhudza kwambiri thanzi komanso moyo watsiku ndi tsiku. Mu 2011, akatswiri adayika mtundu wotchedwa segmental vitiligo mosiyana ndi ena.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Odwala omwe ali ndi vitiligo ali ndi njira zingapo zothandizira, monga systemic glucocorticoids, phototherapy, ndi systemic immunosuppressants. Odwala okhazikika a vitiligo atha kupeza mpumulo ku topical corticosteroids, topical calcineurin inhibitors, phototherapy, ndi njira zopatsira. Kupita patsogolo kwaposachedwa pakumvetsetsa zomwe zimayambitsa matenda a vitiligo kwapangitsa kuti pakhale njira zochizira zomwe zimayang'aniridwa. Pakadali pano, ma JAK inhibitors ndi omwe amalonjeza kwambiri, omwe amapereka kulekerera kwabwino komanso zotulukapo zogwira ntchito, ngakhale ali pachiwopsezo choyambitsa matenda obisika komanso zotsatira zoyipa zomwe zimachitika ndi ma immunosuppressive agents. Kafukufuku wopitilira akufuna kudziwa ma cytokines ofunikira pakukula kwa vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Kuletsa ma cytokines awa kwawonetsa kulonjeza kwa nyama ndi odwala ena. Kuphatikiza apo, kafukufuku wa miRNA-based therapeutics ndi adoptive Treg cell therapy ali mkati.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Palibe mankhwala odziwika bwino a vitiligo. Kwa iwo omwe ali ndi khungu lopepuka, zoteteza ku dzuwa ndi zodzoladzola ndizo zonse zomwe zimalimbikitsidwa. Njira zina zothandizira zingaphatikizepo steroid creams kapena phototherapy.
○ Machiritso
#Phototherapy
#Excimer laser
#Tacrolimus ointment